faricimab: Clinical Trials

14 trials of faricimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 3 recruiting, 1 not yet recruiting, 1 unknown. 14 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 314Completed 9, Recruiting 3, Not yet recruiting 1, Unknown 1
Phase 21Unknown 1

Follow faricimab: new trials by email Literature Review of faricimab trials Research Report on faricimab

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Anti-VEGF Versus Prompt Laser or Observation for Proliferative Sickle Cell Retinopathy (ALPS)
Faricimab Injection for stage 3 or stage 4 Proliferative sickle cell eyes, Vitrectomy, Laser photocoagulation - Proliferative Sickle Cell Retinopathy
Phase 3Not yet recruitingUniversity of Illinois Chicago502026-12-012026-11-06
Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy
Faricimab Injection [Vabysmo] - Polypoidal Choroidal Vasculopathy (PCV), Age Related Macular Degeneration
Phase 3RecruitingYeungnam University College of Medicine502026-03-012026-03-10
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
Vitrectomy, Endolaser, Faricimab - Proliferative Diabetic Retinopathy (PDR)
Phase 3RecruitingJaeb Center for Health Research4262025-08-042026-11-17
A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
Faricimab, Ranibizumab, Sham Procedure - Choroidal Neovascularization Secondary to Pathologic Myopia
Phase 3CompletedHoffmann-La Roche2802024-03-062026-07-31
Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients
Faricimab - Age-Related Macular Degeneration, Diabetic Macular Edema
Phase 2 / Phase 3UnknownSecond Affiliated Hospital, Zhejiang University, School of Medicine302024-03-012024-08-27
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
Faricimab, fluocinolone acetonide - Radiation Retinopathy, Visual Impairment
Phase 3RecruitingJaeb Center for Health Research6002023-11-212026-10-23
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
Faricimab, Sham Procedure, Anti-VEGF Therapy - Neovascular Age-related Macular Degeneration
Phase 3CompletedHoffmann-La Roche10362021-04-192025-10-24
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion
Faricimab, Aflibercept, Sham Procedure - Macular Edema, Central Retinal Vein Occlusion
Phase 3CompletedHoffmann-La Roche7292021-03-022024-08-06
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
Faricimab, Aflibercept, Sham Procedure - Macular Edema, Branch Retinal Vein Occlusion
Phase 3CompletedHoffmann-La Roche5532021-03-022024-08-06
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema
Faricimab, Sham Procedure - Diabetic Macular Edema
Phase 3CompletedHoffmann-La Roche14792020-08-052026-02-09
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
Faricimab, Aflibercept, Sham Procedure - Wet Macular Degeneration
Phase 3CompletedHoffmann-La Roche6582019-03-112025-07-11
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
Faricimab, Aflibercept, Sham Procedure - Wet Macular Degeneration
Phase 3CompletedHoffmann-La Roche6712019-02-192025-07-23
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema
Aflibercept, Faricimab, Sham Procedure - Diabetic Macular Edema
Phase 3CompletedHoffmann-La Roche9512018-10-092025-07-11
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
Aflibercept, Faricimab, Sham Procedure - Diabetic Macular Edema
Phase 3CompletedHoffmann-La Roche9402018-09-052025-07-11

Conditions studied

Retinal Vein Occlusion (3)  ·  Macular Degeneration (2)  ·  Macular Edema (2)  ·  Wet Macular Degeneration (2)  ·  Polypoidal Choroidal Vasculopathy (1)  ·  Vision Disorders (1)

Sponsors

Hoffmann-La Roche (9)  ·  Jaeb Center for Health Research (2)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (1)  ·  University of Illinois Chicago (1)  ·  Yeungnam University College of Medicine (1)

Countries

United States (11)  ·  Germany (9)  ·  Italy (9)  ·  Poland (9)  ·  Spain (9)  ·  France (8)  ·  Hungary (8)  ·  Russia (8)  ·  South Korea (8)  ·  Australia (7)  ·  Hong Kong (7)  ·  Singapore (7)  ·  Taiwan (7)  ·  Argentina (6)  ·  Austria (6)

Top investigators

Panpan Ye, doctor (1)

Results publications

PMID 41534798, PMID 35085502, PMID 35085503, PMID 36246184, PMID 36246941, PMID 36897413, PMID 37294433, PMID 37585454, PMID 38158159, PMID 38280653, PMID 38382813, PMID 38758639, PMID 38852921, PMID 40668667, PMID 41712218, PMID 42753135, PMID 42771326, PMID 36912792, PMID 37955955, PMID 39580145, PMID 40107501, PMID 40496217, PMID 41961203, PMID 42005909, PMID 42622958

NIH funding

2017 (2), 2018 (2), UG1EY014231 (2), 2023 (1)